
Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
---|---|---|---|---|---|
BRO
Brown & Brown
|
$1.3B | $0.99 | 10.51% | 17.12% | $120.18 |
AJG
Arthur J. Gallagher &
|
$3.2B | $2.36 | 15.87% | 89% | $336.95 |
CRVL
CorVel
|
-- | -- | -- | -- | -- |
EHTH
eHealth
|
$46M | -$1.25 | -30.18% | -6.02% | $10.00 |
KINS
Kingstone Companies
|
$44.6M | $0.55 | 22.19% | 48.65% | $22.00 |
MMC
Marsh & McLennan Companies
|
$7B | $2.66 | 11.48% | 20.03% | $231.12 |
Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
---|---|---|---|---|---|---|---|
BRO
Brown & Brown
|
$104.97 | $120.18 | $34.6B | 29.24x | $0.15 | 0.55% | 6.21x |
AJG
Arthur J. Gallagher &
|
$309.92 | $336.95 | $79.4B | 47.68x | $0.65 | 0.81% | 6.04x |
CRVL
CorVel
|
$97.08 | -- | $5B | 52.86x | $0.00 | 0% | 5.64x |
EHTH
eHealth
|
$3.75 | $10.00 | $113.7M | -- | $0.00 | 0% | 0.20x |
KINS
Kingstone Companies
|
$14.89 | $22.00 | $208.5M | 9.36x | $0.00 | 0% | 1.14x |
MMC
Marsh & McLennan Companies
|
$211.98 | $231.12 | $104.4B | 25.98x | $0.82 | 1.54% | 4.20x |
Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
---|---|---|---|---|
BRO
Brown & Brown
|
35.81% | 0.270 | 10.67% | 0.68x |
AJG
Arthur J. Gallagher &
|
36.96% | 0.515 | 14.8% | 0.57x |
CRVL
CorVel
|
-- | 1.116 | -- | 1.35x |
EHTH
eHealth
|
6.89% | -0.950 | 12.54% | 2.49x |
KINS
Kingstone Companies
|
6.13% | 1.828 | 2.34% | 28.29x |
MMC
Marsh & McLennan Companies
|
59.34% | 0.267 | 17.38% | 0.48x |
Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
---|---|---|---|---|---|---|
BRO
Brown & Brown
|
$702M | $452M | 10.16% | 16.34% | 34.3% | $196M |
AJG
Arthur J. Gallagher &
|
$1.8B | $1B | 6.05% | 10.03% | 27.66% | $843.6M |
CRVL
CorVel
|
$58.2M | $33.3M | 33.58% | 33.58% | 14.39% | $14.3M |
EHTH
eHealth
|
$313.9M | $4.8M | 3.8% | 4.17% | 5.64% | $73.7M |
KINS
Kingstone Companies
|
-- | -- | 28.17% | 36.5% | 9.79% | $17M |
MMC
Marsh & McLennan Companies
|
$3.2B | $2B | 13.63% | 29.77% | 29.34% | -$677M |
Arthur J. Gallagher & has a net margin of 23.9% compared to Brown & Brown's net margin of 18.9%. Brown & Brown's return on equity of 16.34% beat Arthur J. Gallagher &'s return on equity of 10.03%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
BRO
Brown & Brown
|
50.69% | $1.15 | $10.6B |
AJG
Arthur J. Gallagher &
|
48.04% | $2.72 | $35.4B |
Brown & Brown has a consensus price target of $120.18, signalling upside risk potential of 14.49%. On the other hand Arthur J. Gallagher & has an analysts' consensus of $336.95 which suggests that it could grow by 8.72%. Given that Brown & Brown has higher upside potential than Arthur J. Gallagher &, analysts believe Brown & Brown is more attractive than Arthur J. Gallagher &.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
BRO
Brown & Brown
|
4 | 7 | 0 |
AJG
Arthur J. Gallagher &
|
7 | 7 | 0 |
Brown & Brown has a beta of 0.819, which suggesting that the stock is 18.067% less volatile than S&P 500. In comparison Arthur J. Gallagher & has a beta of 0.708, suggesting its less volatile than the S&P 500 by 29.209%.
Brown & Brown has a quarterly dividend of $0.15 per share corresponding to a yield of 0.55%. Arthur J. Gallagher & offers a yield of 0.81% to investors and pays a quarterly dividend of $0.65 per share. Brown & Brown pays 15.51% of its earnings as a dividend. Arthur J. Gallagher & pays out 35.92% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
Brown & Brown quarterly revenues are $1.4B, which are smaller than Arthur J. Gallagher & quarterly revenues of $3.7B. Brown & Brown's net income of $331M is lower than Arthur J. Gallagher &'s net income of $704.4M. Notably, Brown & Brown's price-to-earnings ratio is 29.24x while Arthur J. Gallagher &'s PE ratio is 47.68x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brown & Brown is 6.21x versus 6.04x for Arthur J. Gallagher &. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
BRO
Brown & Brown
|
6.21x | 29.24x | $1.4B | $331M |
AJG
Arthur J. Gallagher &
|
6.04x | 47.68x | $3.7B | $704.4M |
CorVel has a net margin of 23.9% compared to Brown & Brown's net margin of 11.41%. Brown & Brown's return on equity of 16.34% beat CorVel's return on equity of 33.58%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
BRO
Brown & Brown
|
50.69% | $1.15 | $10.6B |
CRVL
CorVel
|
25.13% | $0.51 | $322M |
Brown & Brown has a consensus price target of $120.18, signalling upside risk potential of 14.49%. On the other hand CorVel has an analysts' consensus of -- which suggests that it could fall by --. Given that Brown & Brown has higher upside potential than CorVel, analysts believe Brown & Brown is more attractive than CorVel.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
BRO
Brown & Brown
|
4 | 7 | 0 |
CRVL
CorVel
|
0 | 0 | 0 |
Brown & Brown has a beta of 0.819, which suggesting that the stock is 18.067% less volatile than S&P 500. In comparison CorVel has a beta of 0.978, suggesting its less volatile than the S&P 500 by 2.168%.
Brown & Brown has a quarterly dividend of $0.15 per share corresponding to a yield of 0.55%. CorVel offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brown & Brown pays 15.51% of its earnings as a dividend. CorVel pays out -- of its earnings as a dividend. Brown & Brown's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Brown & Brown quarterly revenues are $1.4B, which are larger than CorVel quarterly revenues of $231.5M. Brown & Brown's net income of $331M is higher than CorVel's net income of $26.4M. Notably, Brown & Brown's price-to-earnings ratio is 29.24x while CorVel's PE ratio is 52.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brown & Brown is 6.21x versus 5.64x for CorVel. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
BRO
Brown & Brown
|
6.21x | 29.24x | $1.4B | $331M |
CRVL
CorVel
|
5.64x | 52.86x | $231.5M | $26.4M |
eHealth has a net margin of 23.9% compared to Brown & Brown's net margin of 1.72%. Brown & Brown's return on equity of 16.34% beat eHealth's return on equity of 4.17%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
BRO
Brown & Brown
|
50.69% | $1.15 | $10.6B |
EHTH
eHealth
|
99.6% | -$0.33 | $998.4M |
Brown & Brown has a consensus price target of $120.18, signalling upside risk potential of 14.49%. On the other hand eHealth has an analysts' consensus of $10.00 which suggests that it could grow by 166.67%. Given that eHealth has higher upside potential than Brown & Brown, analysts believe eHealth is more attractive than Brown & Brown.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
BRO
Brown & Brown
|
4 | 7 | 0 |
EHTH
eHealth
|
1 | 4 | 0 |
Brown & Brown has a beta of 0.819, which suggesting that the stock is 18.067% less volatile than S&P 500. In comparison eHealth has a beta of 0.969, suggesting its less volatile than the S&P 500 by 3.055%.
Brown & Brown has a quarterly dividend of $0.15 per share corresponding to a yield of 0.55%. eHealth offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brown & Brown pays 15.51% of its earnings as a dividend. eHealth pays out 55.3% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
Brown & Brown quarterly revenues are $1.4B, which are larger than eHealth quarterly revenues of $113.1M. Brown & Brown's net income of $331M is higher than eHealth's net income of $2M. Notably, Brown & Brown's price-to-earnings ratio is 29.24x while eHealth's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brown & Brown is 6.21x versus 0.20x for eHealth. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
BRO
Brown & Brown
|
6.21x | 29.24x | $1.4B | $331M |
EHTH
eHealth
|
0.20x | -- | $113.1M | $2M |
Kingstone Companies has a net margin of 23.9% compared to Brown & Brown's net margin of 7.69%. Brown & Brown's return on equity of 16.34% beat Kingstone Companies's return on equity of 36.5%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
BRO
Brown & Brown
|
50.69% | $1.15 | $10.6B |
KINS
Kingstone Companies
|
-- | $0.27 | $87.6M |
Brown & Brown has a consensus price target of $120.18, signalling upside risk potential of 14.49%. On the other hand Kingstone Companies has an analysts' consensus of $22.00 which suggests that it could grow by 47.75%. Given that Kingstone Companies has higher upside potential than Brown & Brown, analysts believe Kingstone Companies is more attractive than Brown & Brown.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
BRO
Brown & Brown
|
4 | 7 | 0 |
KINS
Kingstone Companies
|
1 | 0 | 0 |
Brown & Brown has a beta of 0.819, which suggesting that the stock is 18.067% less volatile than S&P 500. In comparison Kingstone Companies has a beta of 0.571, suggesting its less volatile than the S&P 500 by 42.923%.
Brown & Brown has a quarterly dividend of $0.15 per share corresponding to a yield of 0.55%. Kingstone Companies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Brown & Brown pays 15.51% of its earnings as a dividend. Kingstone Companies pays out -- of its earnings as a dividend. Brown & Brown's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
Brown & Brown quarterly revenues are $1.4B, which are larger than Kingstone Companies quarterly revenues of $50.5M. Brown & Brown's net income of $331M is higher than Kingstone Companies's net income of $3.9M. Notably, Brown & Brown's price-to-earnings ratio is 29.24x while Kingstone Companies's PE ratio is 9.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brown & Brown is 6.21x versus 1.14x for Kingstone Companies. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
BRO
Brown & Brown
|
6.21x | 29.24x | $1.4B | $331M |
KINS
Kingstone Companies
|
1.14x | 9.36x | $50.5M | $3.9M |
Marsh & McLennan Companies has a net margin of 23.9% compared to Brown & Brown's net margin of 19.56%. Brown & Brown's return on equity of 16.34% beat Marsh & McLennan Companies's return on equity of 29.77%.
Company | Gross Margin | Earnings Per Share | Invested Capital |
---|---|---|---|
BRO
Brown & Brown
|
50.69% | $1.15 | $10.6B |
MMC
Marsh & McLennan Companies
|
45.48% | $2.79 | $34.8B |
Brown & Brown has a consensus price target of $120.18, signalling upside risk potential of 14.49%. On the other hand Marsh & McLennan Companies has an analysts' consensus of $231.12 which suggests that it could grow by 9.03%. Given that Brown & Brown has higher upside potential than Marsh & McLennan Companies, analysts believe Brown & Brown is more attractive than Marsh & McLennan Companies.
Company | Buy Ratings | Hold Ratings | Sell Ratings |
---|---|---|---|
BRO
Brown & Brown
|
4 | 7 | 0 |
MMC
Marsh & McLennan Companies
|
4 | 12 | 1 |
Brown & Brown has a beta of 0.819, which suggesting that the stock is 18.067% less volatile than S&P 500. In comparison Marsh & McLennan Companies has a beta of 0.796, suggesting its less volatile than the S&P 500 by 20.374%.
Brown & Brown has a quarterly dividend of $0.15 per share corresponding to a yield of 0.55%. Marsh & McLennan Companies offers a yield of 1.54% to investors and pays a quarterly dividend of $0.82 per share. Brown & Brown pays 15.51% of its earnings as a dividend. Marsh & McLennan Companies pays out 37.27% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
Brown & Brown quarterly revenues are $1.4B, which are smaller than Marsh & McLennan Companies quarterly revenues of $7.1B. Brown & Brown's net income of $331M is lower than Marsh & McLennan Companies's net income of $1.4B. Notably, Brown & Brown's price-to-earnings ratio is 29.24x while Marsh & McLennan Companies's PE ratio is 25.98x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Brown & Brown is 6.21x versus 4.20x for Marsh & McLennan Companies. Usually stocks with elevated PS ratios are considered overvalued.
Company | Price/Sales Ratio | Price/Earnings Ratio | Quarterly Revenue | Quarterly Net Income |
---|---|---|---|---|
BRO
Brown & Brown
|
6.21x | 29.24x | $1.4B | $331M |
MMC
Marsh & McLennan Companies
|
4.20x | 25.98x | $7.1B | $1.4B |
Signup to receive the latest stock alerts
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Market Cap: $4.2T
P/E Ratio: 58x
Market Cap: $3.8T
P/E Ratio: 43x
Market Cap: $3.1T
P/E Ratio: 35x
SharpLink Gaming [SBET] is down 2.6% over the past day.
Exodus Movement [EXOD] is down 4.14% over the past day.
Unity Software [U] is up 7.51% over the past day.